When oral nerve pain medications like gabapentin or duloxetine cause unbearable drowsiness, dizziness, or simply stop working, a topical cream or patch applied directly to the skin can provide meaningful relief without those systemic side effects. The strongest clinical evidence points to two FDA-approved options — the capsaicin 8% patch (brand name Qutenza) and the lidocaine 5% patch — as effective alternatives for people who cannot tolerate or do not respond to pills. In clinical trials, 44% of patients with postherpetic neuralgia achieved at least 30% pain reduction after a single Qutenza application, with relief lasting an average of five months.
This matters enormously for people living with dementia or caring for someone who does. Nerve pain is common in older adults, and the oral medications used to treat it — gabapentinoids, tricyclic antidepressants, SNRIs — carry risks of cognitive impairment, sedation, and dangerous drug interactions that are especially concerning in aging brains. A topical approach that stays local and avoids the bloodstream can be a genuine turning point. This article covers what the FDA-approved topical options actually are, how well they work based on published trial data, a promising newer cream still under investigation, and why you should be skeptical of expensive compounded pain creams despite their popularity.
Table of Contents
- Why Do Topical Nerve Pain Treatments Work When Oral Medications Fail?
- What Are the FDA-Approved Topical Options and How Effective Are They?
- Topical Phenytoin Cream — A Promising but Investigational Option
- Compounded Pain Creams — Why the Popular Choice May Not Be Worth the Cost
- Special Considerations for People With Dementia
- How to Talk to Your Doctor About Topical Nerve Pain Options
- Where Topical Nerve Pain Treatment Is Heading
- Conclusion
- Frequently Asked Questions
Why Do Topical Nerve Pain Treatments Work When Oral Medications Fail?
Nearly half of patients do not achieve adequate pain relief from first-line oral therapies such as gabapentinoids and antidepressants, and many who do get some benefit eventually discontinue treatment because the side effects become intolerable. For a 74-year-old with diabetic neuropathy who is also managing early-stage Alzheimer’s, adding gabapentin to an already complex medication regimen introduces real risks — increased confusion, fall risk from dizziness, and unpredictable interactions with cholinesterase inhibitors or memantine. This is not a theoretical concern. It is the daily reality of dementia care. Topical agents work differently. They deliver the active drug directly to the nerve fibers in the skin where the pain originates, resulting in minimal systemic absorption.
That means fewer drug-drug interactions, no sedation, and no cognitive side effects. The medication stays where it is needed rather than circulating through the liver, kidneys, and brain. For caregivers managing someone with both neuropathic pain and cognitive decline, this distinction between local and systemic treatment is not a minor detail — it is the entire point. It is worth noting, however, that not all nerve pain responds to topical treatment. These options work best for localized, peripheral neuropathic pain — the burning in the feet from diabetic neuropathy, the stabbing sensation along a rib from shingles. Central neuropathic pain or widespread pain conditions like fibromyalgia are a different story and generally require systemic approaches.
What Are the FDA-Approved Topical Options and How Effective Are They?
Only three topical analgesics are currently FDA-approved for neuropathic pain: the capsaicin 8% patch, the lidocaine 5% patch, and the lidocaine 1.8% topical system. That is a surprisingly short list given how many compounded creams and over-the-counter products line pharmacy shelves. The capsaicin 8% patch (Qutenza) holds the broadest approval, covering both postherpetic neuralgia and diabetic peripheral neuropathy. The lidocaine 5% patch is approved specifically for postherpetic neuralgia, though moderate evidence supports its use in diabetic neuropathy, idiopathic neuropathy, and postsurgical neuropathy as well. The capsaicin patch works by overwhelming and then desensitizing the TRPV1 pain receptors in the skin. A meta-analysis of Qutenza clinical trial data found that 44% of postherpetic neuralgia patients and 41% of HIV-associated neuropathy patients achieved at least 30% pain reduction. Complete pain relief was less common but still notable — 11% of postherpetic neuralgia patients and 7% of HIV-associated neuropathy patients reported total resolution of pain within two to twelve weeks of treatment.
Mean onset of response was 3.4 days for postherpetic neuralgia and 6.5 days for HIV-associated neuropathy. Perhaps most impressive, the mean duration of relief after a single treatment was five months. However, the capsaicin 8% patch is not something you pick up at the drugstore. It requires application in a clinical setting by a healthcare provider, takes 30 to 60 minutes to apply, and involves a minimum three-month interval between treatments. The application itself can cause significant burning and redness at the site. For someone with dementia who may not understand why a painful procedure is being done to them, this requires careful consideration, preparation, and possibly pre-treatment with a topical numbing agent. A separate 12-week double-blind trial in diabetic peripheral neuropathy confirmed that a single 30-minute application significantly improved both pain and sleep quality compared to placebo — the sleep finding being especially relevant for dementia caregivers who know how much disrupted sleep worsens cognition.
Topical Phenytoin Cream — A Promising but Investigational Option
Phenytoin is an old seizure medication that has found a surprising second life as a topical nerve pain treatment. Applied as a 10% to 20% cream directly to the painful area, topical phenytoin has shown striking results in early studies — a mean pain reduction of 61.2% in case series, with onset of relief in approximately 16 minutes and duration of about 8 hours per application. Unlike the capsaicin patch, which requires a clinic visit, phenytoin cream can be applied at home, and because absorption through the skin is minimal, it carries no systemic side effects. A February 2025 study published in MDPI Pharmaceuticals examined topical phenytoin specifically in painful diabetic neuropathy and found something useful for clinical practice: patients who experienced a fast analgesic response during initial testing were more likely to achieve prolonged pain relief with extended use.
This suggests a straightforward way to identify who will benefit — try it once and see if you get rapid relief. The critical caveat is that topical phenytoin remains investigational. It is not FDA-approved for neuropathic pain, and the evidence base consists largely of case series and small studies rather than large randomized controlled trials. A doctor would need to prescribe it as an off-label compounded medication, and insurance typically will not cover it. For families dealing with both neuropathy and dementia, the appeal of a no-side-effect topical with fast onset is obvious, but it should be discussed honestly with a neurologist or pain specialist who understands where the evidence currently stands.
Compounded Pain Creams — Why the Popular Choice May Not Be Worth the Cost
Walk into many pain clinics and you will hear about custom-compounded topical creams containing combinations of ketamine, gabapentin, clonidine, lidocaine, and other ingredients mixed to order by a compounding pharmacy. These creams are marketed as personalized pain solutions, and they can cost hundreds of dollars per tube. The pitch sounds reasonable — combine multiple pain-fighting drugs in one topical application. But the evidence tells a different story. A major randomized controlled trial of 399 patients, published in the Annals of Internal Medicine in 2019, tested compounded pain creams containing ketamine, gabapentin, clonidine, and lidocaine against placebo for neuropathic pain. The result was decisive: the compounded creams were no better than placebo, with a mean difference of just -0.1 points on a pain scale (95% confidence interval: -0.8 to 0.5).
Johns Hopkins Medicine, which led the study, was blunt in its assessment — the research pushes back on the claimed benefits of these products. Beyond the efficacy question, compounded topical creams have inconsistent batch-to-batch quality because they are mixed individually rather than manufactured under standardized pharmaceutical conditions. They are typically not covered by insurance, and the out-of-pocket costs can be substantial. For families already stretched thin by the financial demands of dementia care, spending hundreds of dollars monthly on a cream that performed no better than a placebo in the largest trial to date is a real concern. The FDA-approved options — capsaicin 8% and lidocaine 5% — have the evidence to support their use. Expensive custom blends, as a general rule, do not.
Special Considerations for People With Dementia
Treating nerve pain in someone with cognitive impairment introduces challenges that pain guidelines rarely address. A person with moderate to advanced dementia may not be able to articulate where the pain is, how severe it is, or whether a treatment is helping. Behavioral signs — agitation, grimacing, resistance to being touched in certain areas, disrupted sleep — often serve as proxies for pain assessment, and these same behaviors can be mistakenly attributed to the dementia itself rather than to an underlying physical cause. Topical treatments offer a practical advantage here beyond just avoiding systemic side effects. A caregiver can apply a lidocaine patch to a specific area and observe whether agitation decreases or sleep improves over the following days, creating a kind of diagnostic trial.
If the behavioral symptoms improve, it confirms that pain was contributing. If they do not, the patch can simply be removed with no lingering systemic effects and no need for a taper. Oral medications do not offer this kind of clean on-off testing, especially in patients who may already be on multiple drugs. One warning that bears emphasis: the capsaicin 8% patch causes a painful burning sensation during and after application. In someone who cannot understand what is happening or why, this can cause extreme distress and even combative behavior. If Qutenza is being considered for a person with dementia, the clinical team should have a clear plan for managing the application discomfort, and the caregiver or family member should be part of that conversation.
How to Talk to Your Doctor About Topical Nerve Pain Options
Many primary care physicians default to oral gabapentin or pregabalin as a first-line treatment for neuropathy because that is what the standard guidelines recommend. If those medications are causing cognitive problems or not providing relief, it is entirely appropriate to ask specifically about FDA-approved topical alternatives. Mention the capsaicin 8% patch by name (Qutenza) and ask whether a referral to a pain specialist or neurologist would be appropriate for supervised application.
For the lidocaine 5% patch, a prescription from the primary care doctor is usually straightforward. If a provider suggests a compounded multi-ingredient cream, ask them directly about the 2019 Annals of Internal Medicine trial that found these creams no better than placebo. Not every doctor will be aware of that study, and bringing it up is not adversarial — it is informed advocacy, exactly the kind that leads to better care.
Where Topical Nerve Pain Treatment Is Heading
The development of topical phenytoin cream as a potential neuropathic pain treatment represents a broader shift in pain medicine toward localized therapies that minimize systemic exposure. Researchers are also investigating other repurposed drugs in topical formulations, and the 2025 review published in Pain Medicine suggests that the field is actively working to expand the short list of FDA-approved topical options for neuropathy. For the dementia care community, this trajectory is encouraging.
Every new pain treatment that works locally rather than systemically is a potential tool for managing pain without worsening cognition. The current evidence already supports capsaicin 8% and lidocaine 5% as genuine alternatives when oral medications fail. As the research on topical phenytoin and other agents matures, the options are likely to grow — and with them, the ability to treat the whole person rather than forcing a choice between pain relief and mental clarity.
Conclusion
When oral nerve pain medications fail because of side effects, drug interactions, or simple ineffectiveness, FDA-approved topical options like the capsaicin 8% patch and the lidocaine 5% patch offer clinically proven alternatives that avoid systemic exposure. The capsaicin patch in particular has demonstrated meaningful pain reduction in nearly half of patients treated, with relief lasting months from a single application. Topical phenytoin cream shows early promise as a fast-acting option, though it remains investigational.
Compounded multi-ingredient pain creams, despite their popularity and high price tags, failed to outperform placebo in the largest trial conducted to date. For families navigating both neuropathic pain and dementia, topical treatments are not just a backup plan — they may be the better first choice. The absence of cognitive side effects, the minimal drug interactions, and the ability to start and stop treatment cleanly make these options especially well suited to the complex realities of caring for an aging brain. Talk to your doctor, ask about the specific FDA-approved patches by name, and do not let anyone sell you an expensive compounded cream without first asking what the evidence actually shows.
Frequently Asked Questions
Can I buy the capsaicin 8% patch over the counter?
No. The capsaicin 8% patch (Qutenza) is a prescription product that must be applied by a healthcare professional in a clinical setting. Over-the-counter capsaicin creams contain much lower concentrations (typically 0.025% to 0.1%) and are not equivalent in effectiveness.
Is the lidocaine 5% patch safe to use alongside dementia medications?
Generally yes. Because the lidocaine patch delivers the drug locally with minimal systemic absorption, drug interactions with dementia medications like donepezil, rivastigmine, or memantine are not a significant concern. However, always confirm with your prescribing physician.
How quickly does the capsaicin 8% patch start working?
In clinical trials, the mean onset of response was 3.4 days for postherpetic neuralgia and 6.5 days for HIV-associated neuropathy. Relief from a single application lasted an average of five months.
Are compounded pain creams ever worth trying?
The strongest evidence to date — a randomized trial of 399 patients published in the Annals of Internal Medicine — found that compounded creams containing ketamine, gabapentin, clonidine, and lidocaine were no better than placebo for neuropathic pain. They are also typically not covered by insurance and have inconsistent quality. The FDA-approved patches are a better starting point.
Can topical phenytoin cream be prescribed now?
A doctor can prescribe it off-label through a compounding pharmacy, but it is not FDA-approved for neuropathic pain. The evidence is promising but still limited to case series and small studies. Discuss the current state of the research with a pain specialist before pursuing this option.
What if my family member with dementia cannot tolerate the burning from the capsaicin patch?
This is a legitimate concern. The capsaicin 8% patch causes significant burning during application that can last hours afterward. For someone with dementia who cannot understand the procedure, this may cause extreme distress. The lidocaine 5% patch, which causes no pain on application, may be a more appropriate first option in this population.
